Aspira Pathlab & Diagnostics Share Price
Sector: Healthcare Facilities
61.60 +2.90 (4.94%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
55.80
Today’s High
61.63
52 Week Low
25.00
52 Week High
106.78
Key Metrics
- Market Cap (In Cr) 63.41
- Beta 0.16
- Div. Yield (%) 0
- P/B 6.25
- TTM P/E 72.3
- Sector P/E 0
- Open Price 61.63
- Prev Close 58.7
Aspira Pathlab & Diagnostics Analysis
Price Analysis
-
1 Week4.41%
-
3 Months-2.75%
-
6 Month-8.98%
-
YTD3.53%
-
1 Year101.83%
Risk Meter
- 52% Low risk
- 52% Moderate risk
- 52% Balanced Risk
- 52% High risk
- 52% Extreme risk
Aspira Pathlab & Diagnostics Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 13.2
- Selling/ General/ Admin Expenses Total
- 6.2
- Depreciation/ Amortization
- 1.54
- Other Operating Expenses Total
- 5.57
- Total Operating Expense
- 15.93
- Operating Income
- -2.73
- Net Income Before Taxes
- -2.67
- Net Income
- -2.67
- Diluted Normalized EPS
- -2.6
- Period
- 2024
- Total Assets
- 14.71
- Total Liabilities
- 4.57
- Total Equity
- 10.14
- Tangible Book Valueper Share Common Eq
- 7.26
- Period
- 2024
- Cashfrom Operating Activities
- 1.05
- Cashfrom Investing Activities
- 0.14
- Cashfrom Financing Activities
- -0.95
- Net Changein Cash
- 0.24
- Period
- 2023
- Total Revenue
- 14.46
- Selling/ General/ Admin Expenses Total
- 5.59
- Depreciation/ Amortization
- 1.59
- Other Operating Expenses Total
- 4.77
- Total Operating Expense
- 14.45
- Operating Income
- 0.01
- Net Income Before Taxes
- -0.09
- Net Income
- -0.09
- Diluted Normalized EPS
- -0.09
- Period
- 2023
- Total Assets
- 17.34
- Total Liabilities
- 4.59
- Total Equity
- 12.75
- Tangible Book Valueper Share Common Eq
- 9.77
- Period
- 2023
- Cashfrom Operating Activities
- -0.01
- Cashfrom Investing Activities
- 0.16
- Cashfrom Financing Activities
- -0.93
- Net Changein Cash
- -0.79
- Period
- 2022
- Total Revenue
- 19.54
- Selling/ General/ Admin Expenses Total
- 5.02
- Depreciation/ Amortization
- 1.64
- Other Operating Expenses Total
- 5.01
- Total Operating Expense
- 14.8
- Operating Income
- 4.74
- Net Income Before Taxes
- 4.46
- Net Income
- 4.46
- Diluted Normalized EPS
- 4.33
- Period
- 2022
- Total Assets
- 18.14
- Total Liabilities
- 5.35
- Total Equity
- 12.79
- Tangible Book Valueper Share Common Eq
- 9.75
- Period
- 2022
- Cashfrom Operating Activities
- 2.03
- Cashfrom Investing Activities
- -0.51
- Cashfrom Financing Activities
- -1.35
- Net Changein Cash
- 0.17
- Period
- 2021
- Total Revenue
- 15.21
- Selling/ General/ Admin Expenses Total
- 4.03
- Depreciation/ Amortization
- 1.44
- Other Operating Expenses Total
- 5.03
- Total Operating Expense
- 13.14
- Operating Income
- 2.07
- Net Income Before Taxes
- 1.38
- Net Income
- 1.38
- Diluted Normalized EPS
- 1.45
- Period
- 2021
- Total Assets
- 11.78
- Total Liabilities
- 3.46
- Total Equity
- 8.31
- Tangible Book Valueper Share Common Eq
- 5.36
- Period
- 2021
- Cashfrom Operating Activities
- 5.67
- Cashfrom Investing Activities
- -0.09
- Cashfrom Financing Activities
- -2.17
- Net Changein Cash
- 3.41
- Period
- 2020
- Total Revenue
- 8.42
- Selling/ General/ Admin Expenses Total
- 4.95
- Depreciation/ Amortization
- 1.66
- Other Operating Expenses Total
- 3.31
- Total Operating Expense
- 11.9
- Operating Income
- -3.49
- Net Income Before Taxes
- -4.21
- Net Income
- -4.24
- Diluted Normalized EPS
- -4.95
- Period
- 2020
- Total Assets
- 14.34
- Total Liabilities
- 10.53
- Total Equity
- 3.8
- Tangible Book Valueper Share Common Eq
- 1.23
- Period
- 2020
- Cashfrom Operating Activities
- -1.87
- Cashfrom Investing Activities
- 0.24
- Cashfrom Financing Activities
- 1.27
- Net Changein Cash
- -0.35
- Period
- 2019
- Total Revenue
- 7.64
- Selling/ General/ Admin Expenses Total
- 4.47
- Depreciation/ Amortization
- 1.23
- Other Operating Expenses Total
- 4.15
- Total Operating Expense
- 12.11
- Operating Income
- -4.48
- Net Income Before Taxes
- -5.18
- Net Income
- -5.18
- Diluted Normalized EPS
- -6.33
- Period
- 2019
- Total Assets
- 14.8
- Total Liabilities
- 9.61
- Total Equity
- 5.19
- Tangible Book Valueper Share Common Eq
- 3.03
- Period
- 2019
- Cashfrom Operating Activities
- -3.39
- Cashfrom Investing Activities
- -1.97
- Cashfrom Financing Activities
- 5.23
- Net Changein Cash
- -0.12
- Period
- 2024-12-31
- Total Revenue
- 5.41
- Selling/ General/ Admin Expenses Total
- 1.97
- Depreciation/ Amortization
- 0.39
- Other Operating Expenses Total
- 1.82
- Total Operating Expense
- 5.03
- Operating Income
- 0.38
- Net Income Before Taxes
- 0.31
- Net Income
- 0.31
- Diluted Normalized EPS
- 0.3
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 6.18
- Selling/ General/ Admin Expenses Total
- 1.75
- Depreciation/ Amortization
- 0.36
- Other Operating Expenses Total
- 1.97
- Total Operating Expense
- 5.18
- Operating Income
- 0.99
- Net Income Before Taxes
- 0.99
- Net Income
- 0.99
- Diluted Normalized EPS
- 0.96
- Period
- 2024-09-30
- Total Assets
- 15.82
- Total Liabilities
- 4.64
- Total Equity
- 11.18
- Tangible Book Valueper Share Common Eq
- 8.27
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1.83
- Cashfrom Investing Activities
- -0.14
- Cashfrom Financing Activities
- -0.47
- Net Changein Cash
- 1.23
- Period
- 2024-06-30
- Total Revenue
- 4.64
- Selling/ General/ Admin Expenses Total
- 1.66
- Depreciation/ Amortization
- 0.38
- Other Operating Expenses Total
- 1.75
- Total Operating Expense
- 4.66
- Operating Income
- -0.03
- Net Income Before Taxes
- 0.05
- Net Income
- 0.05
- Diluted Normalized EPS
- 0.05
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3.82
- Selling/ General/ Admin Expenses Total
- 1.64
- Depreciation/ Amortization
- 0.38
- Other Operating Expenses Total
- 1.59
- Total Operating Expense
- 4.31
- Operating Income
- -0.49
- Net Income Before Taxes
- -0.5
- Net Income
- -0.5
- Diluted Normalized EPS
- -0.49
- Period
- 2024-03-31
- Total Assets
- 14.71
- Total Liabilities
- 4.57
- Total Equity
- 10.14
- Tangible Book Valueper Share Common Eq
- 7.26
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1.05
- Cashfrom Investing Activities
- 0.14
- Cashfrom Financing Activities
- -0.95
- Net Changein Cash
- 0.24
- Period
- 2023-12-31
- Total Revenue
- 3.46
- Selling/ General/ Admin Expenses Total
- 1.62
- Depreciation/ Amortization
- 0.38
- Other Operating Expenses Total
- 1.49
- Total Operating Expense
- 4.22
- Operating Income
- -0.75
- Net Income Before Taxes
- -0.74
- Net Income
- -0.74
- Diluted Normalized EPS
- -0.72
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Aspira Pathlab & Diagnostics Technical
Moving Average
SMA
- 5 Day56.74
- 10 Day59.44
- 20 Day63.14
- 50 Day73.05
- 100 Day71.29
- 300 Day58.89
Aspira Pathlab & Diagnostics Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Lotus Eye Hospital And Institute
- 74.39
- 0.29
- 0.39
- 91
- 53
- 154.7
- Fortis Malar Hospitals
- 74.7
- 0.31
- 0.42
- 98.7
- 51.01
- 140
- Aspira Pathlab & Diagnostics
- 61.6
- 2.9
- 4.94
- 106.78
- 25
- 63.41
- N G Industries
- 164.5
- 6.75
- 4.28
- 205.5
- 145
- 55.11
- Tejnaksh Healthcare
- 22.25
- 0.61
- 2.82
- 30.5
- 20.5
- 45.4
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Lotus Eye Hospital And Institute
- 52.52
- 2.57
- 4.65
- 6.09
- Fortis Malar Hospitals
- 18.17
- 1.27
- 1.1
- 1.17
- Aspira Pathlab & Diagnostics
- -
- 5.96
- -2.56
- -1.64
- N G Industries
- 10.51
- 1.46
- 18.04
- 21.38
- Tejnaksh Healthcare
- 24.87
- 1.87
- 11.13
- 16.21
Aspira Pathlab & Diagnostics Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 16-May-25
- Audited Results
- 07-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 28-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 10-Feb-24
- Quarterly Results
- 11-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 27-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 27-Sept-24
- 27-Aug-24
- AGM
- 26-Sept-23
- 23-Aug-23
- AGM
- 25-Mar-23
- 20-Feb-23
- POM



